###begin article-title 0
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 90 98 <span type="species:ncbi:9606">Patients</span>
c.1810C>T Polymorphism of NTRK1 Gene is associated with reduced Survival in Neuroblastoma Patients
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
TrkA (encoded by NTRK1 gene), the high-affinity tyrosine kinase receptor for neurotrophins, is involved in neural crest cell differentiation. Its expression has been reported to be associated with a favourable prognosis in neuroblastoma. Therefore, the entire coding sequence of NTRK1 gene has been analysed in order to identify mutations and/or polymorphisms which may alter TrkA receptor expression.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 67 75 <span type="species:ncbi:9606">patients</span>
DNA was extracted from neuroblastomas of 55 Polish and 114 Italian patients and from peripheral blood leukocytes of 158 healthy controls. Denaturing High-Performance Liquid Chromatography (DHPLC) and Single-Strand Conformation Polymorphism (SSCP) analysis were used to screen for sequence variants. Genetic changes were confirmed by direct sequencing and correlated with biological and clinical data.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 437 447 437 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In-silico </italic>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
Three previously reported and nine new single nucleotide polymorphisms were detected. c.1810C>T polymorphism present in 8.7% of cases was found to be an independent marker of disease recurrence (OR = 13.3; p = 0.009) associated with lower survival rates (HR = 4.45 p = 0.041). c.1810C>T polymorphism's unfavourable prognostic value was most significant in patients under 18 months of age with no MYCN amplification (HR = 26; p = 0.008). In-silico analysis of the c.1810C>T polymorphism suggests that the substitution of the corresponding amino acid residue within the conservative region of the tyrosine kinase domain might theoretically interfere with the functioning of the TrkA protein.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 127 135 <span type="species:ncbi:9606">children</span>
NTRK1 c.1810C>T polymorphism appears to be a new independent prognostic factor of poor outcome in neuroblastoma, especially in children under 18 months of age with no MYCN amplification.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 162 168 <span type="species:ncbi:9606">infant</span>
Neuroblastoma (NB), a tumour of the peripheral nervous system arising from embryonal neural crest cells (NCCs), is the foremost malignant neoplasm of neonate and infant [1]. It demonstrates considerable diversity in clinical behaviour, ranging from spontaneous regression or maturation to rapid progression despite aggressive therapy [2]. Among molecular factors influencing the clinical outcome of neuroblastoma, the expression of TrkA has been associated with favourable prognosis [3].
###end p 10
###begin p 11
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 898 899 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1145 1146 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
TrkA is a member of a Trk family of tyrosine kinase receptor for nerve growth factor (NGF) and other neurotrophins. TrkA primarily regulates growth, differentiation and programmed cell death of neurons in both peripheral and central nervous systems [4]. Formation of the neuronal network during maturation of the peripheral nervous system is a complex process that is rigorously governed by the interactions of neurotrophins with their respective Trk receptors [5]. Interestingly, TrkA expression may be involved both in regulation of cell differentiation and in induction of programmed cell death of NCCs sympathoadrenal lineage. Consequently, alterations in the genes of the Trk family may result in oncogenic transformation of the neural crest derivatives [6]. In NBs, the amount of NGF in the tumour microenvironment and expression of TrkA receptor has a profound effect on cellular behaviour [7]. Tumour cells expressing TrkA undergo cell differentiation in the presence of NGF [8], while withdrawal of NGF induces apoptosis. Finally, as previously reported, TrkA expression is a crucial factor for spontaneous regression of neuroblastoma [5].
###end p 11
###begin p 12
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1</italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 252 260 252 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo </italic>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 270 277 <span type="species:ncbi:9606">patient</span>
Human TrkA coding gene (named NTRK1) maps to chromosome 1q21-q22 and is composed of 17 exons [9,10]. Neither germ-line nor somatic gain-of-function mutations of the NTRK1 gene have been observed in any human neoplasia [11-15], except for one case of a de novo AML. That patient was found to carry NTRK1 S677N mutation that might interfere with the tyrosine kinase (TK) activity [11]. A small number of polymorphisms of unknown physiological significance has been reported in a few cases of prostate cancer, papillary thyroid carcinoma and NB [13-15]. Inborn inactivating mutations of NTRK1 gene are responsible for neurodevelopmental abnormalities known as CIPA (Congenital Insensitivity to Pain with Anhidrosis; MIM#256800), a rare recessive genetic disease [16]. Interestingly, the clinical profile of CIPA does not include predisposition to cancer.
###end p 12
###begin p 13
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
Although many publications provide information on the role of TrkA expression in NB [17], only one pilot study analysed partially NTRK1 gene sequence in NBs [13]. Therefore, we performed mutational analysis of the entire coding sequence of the NTRK1 gene to identify somatic mutations and/or polymorphisms which might alter TrkA expression and to evaluate clinical and biological consequences of their incidence for the patients with NB.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">children</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
Fifty-five NB patients treated in Polish paediatric oncologic centres and 114 NB patients retrieved from the Italian Neuroblastoma Group were enrolled into the study. Main clinical and biological characteristics of the patients, including age, stage of the disease, histology subtype in accordance with International Neuroblastoma Pathology Classification (INPC), MYCN amplification status and 1p36 chromosome deletion, are shown in Table 1. A control group of 158 healthy anonymous adult volunteers without history of hereditary cancer or other chronic disorders was included into the study on the basis of a detailed questionnaire and clinical examination. Written informed consent was obtained from the relevant guardians of the children and from patients and controls themselves, whenever eligible. The study was approved by the Ethics Committee of the Medical University of Gdansk, Poland.
###end p 15
###begin p 16
###xml 50 58 <span type="species:ncbi:9606">Patients</span>
Clinical and biological Features of Neuroblastoma Patients.
###end p 16
###begin p 17
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Abbreviations: PL - Polish, IT - Italian group of patients; FH - favorable, UH - unfavorable histology: in accordance to International Neuroblastoma Pathology Classification (INPC)
###end p 17
###begin p 18
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 818 820 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
DNA was extracted from fresh-frozen and/or paraffin-embedded tumour samples obtained during initial surgery procedures and from leukocytes of healthy controls. Tumour DNA was analysed because peripheral blood samples were not readily attainable from NB patients representing a number of oncologic centres from two countries. After digestion with proteinase K, DNA was purified by standard phenol-chloroform procedure [18]. All coding exons and flanking intronic (ca. 50 bp) sequences of NTRK1 gene were screened for mutations using two complementary techniques: SSCP (single-strand conformation polymorphism) analysis and DHPLC (denaturing high performance liquid chromatography). SSCP was performed in 12% polyacrylamide gels run at 200V for 2-4 hrs in 4degreesC followed by silver staining, as previously described [15]. DHPLC was performed on an automated WAVE System 3500 (Transgenomic Inc., San Jose, CA). Samples showing variation in SSCP banding pattern and/or abnormal profile of elution by DHPLC as well as a few randomly selected negative samples were subject to sequencing. DNA sequencing reactions were performed using capillary-based ABI 3100 Genetic Analyser (Applied Biosystems Inc., Foster City, CA).
###end p 18
###begin p 19
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 689 695 689 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
Selected bioinformatic tools were used to assess the effect of sequence variants on the structure and function of the receptor. Alignment analysis of 4606 sequences similar to TrkA retrieved from Pfam database [19] (as for 11.2008) was used to identify conservative amino acid residues. Protein Data Bank [20] (last accessed 11.2008) was searched to identify the most structurally similar model of the TK domain, which was later used as a template for construction of the TrkA homology model. The fold recognition methods were used . The homology model was used to map mutated residues onto the three-dimensional structure of a prototypical kinase domain. Haplotype analysis of the entire NTRK1 gene sequence (chromosome 1q 155,097,295-155,118,266) was performed using data representative for the four distinct populations retrieved from International HapMap Project database [21] ( last accessed 05.2008) using Haploview software [22].
###end p 19
###begin p 20
###xml 502 508 502 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
In all statistical analyses, allele frequencies were compared between case and control subjects within each population by chi-squared tests with adequate corrections, Fisher exact probability tests with Freeman-Halton extension for 2 x 3 tables and in the two populations combined by the Cochran-Mantel-Haenszel statistics. MAF (minor allele frequency) <5% was the criterion for exclusion from further statistical analysis. Unconditional logistic regression was used to examine the association between NTRK1 genotypes and clinical and biological characteristics of the disease. The dichotomous NB prognostic risk factors used as covariates are summarised in Table 1. The effect of the genotypes on long-time survival rates were analysed using Kaplan-Meier survival probability estimates, log-rank tests and Cox hazard proportional models. In the analysis of the two populations combined, an indicator variable for the study population (Poland versus Italy) was added to the models.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
Nine new NTRK1 gene variants were identified in NB samples. Four of them were located in the coding regions: c.482G>A, c.505G>A in exon 5; c.1785G>A, c.1858_1859delinsTC in exon 15 (Figure 1; Electronic supplementary material - additional file 1). Besides, three previously reported single nucleotide polymorphisms (SNPs) were detected [15-17]: c.1674G>A(rs6334), c.1810C>T(rs6336) and c.1887C>T(rs6337). (Figure 1; Electronic supplementary material - additional file 2). A nested study of the corresponding germline DNA confirmed presence of the SNPs at constitutional level.
###end p 22
###begin p 23
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sequence variants of the <italic>NTRK1 </italic>gene identified in the present study</bold>
Sequence variants of the NTRK1 gene identified in the present study. The structure of TrkA receptor. Extracellular part of the protein consists of: two cysteine clusters (Cys); three leucine-rich motifs (LRM) and two immunoglobulin-like C2 domains (Ig-C2). It is followed by a short transmembrane portion (TM), and intracellular juxtamembrane domain (JM) and tyrosine kinase domain (TK). * - newly identified sequence variants, circled - the SNPs having MAF (minor allele frequency) value >5%, arrows - exonic localization of the variants, dishes - intronic localization of the variants.
###end p 23
###begin p 24
###xml 101 111 101 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico </italic>
###xml 800 805 796 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1luf </italic>
###xml 806 808 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1080 1082 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1132 1137 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1luf </italic>
###xml 1256 1257 1252 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
For all non-synonymous variants (i.e. c.482G>A, c.505G>A, c.1785G>A, c.1810C>T, c.1858_1859delinsTC) in silico structure-function analyses have been performed. c.482G>A codes the last residue of the third leucine-rich motifs region. It is the last residue of the alpha-helix and the replaced amino acid has similar physical characteristics, thus the probability of its influence on protein structure is rather low. Similarly, c.505G>A most likely does not affect the protein structure, since it encodes a substitution of a residue in a non-structuralised fragment of the protein. The remaining three non-synonymous SNPs encode residues of the TK kinase, among which residue 604 (coded by c.1810C>T) is the only one evolutionarily conserved. We found an experimentally determined structure of MuSK TK 1luf [23] to have the highest similarity with the TrkA TK domain. Sequence alignment revealed that all of the mutated TK residues lie in the kinase insert (TrkA residues 602-622) at the C-terminal lobe. This is a region of variable size and unknown function in many receptor TKs [23]. Homology modelling of TrkA TK domain, based on 1luf structure file, allowed us to visualise the localisation of His604 relative to the domain's functional regions (Figure 2).
###end p 24
###begin p 25
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Homology model of the TrkA TK domain</bold>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1luf </italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al. </italic>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 937 939 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Homology model of the TrkA TK domain. The model was obtained using rat MuSK kinase structure 1luf [23]. Activation loop (orange) and catalytic loop (blue) are indicated in accordance to de Pablo et al. [31]. The kinase insert fragment of kinase domain constitutes a loop joining two alpha-helices. Most of its residues are missing in the crystal structure presumably due to the loop's high conformational flexibility and therefore not present in homology model (depicted as green beads). The His604 residue (red) is located at the end of structurally determined helical region, distant from ATPase active site (arrow). It may, however, be involved in interactions with residues of the unstructured loop region. Although the function of this loop is not yet known, it may be speculated that it is involved in specific for TrkA interactions with secondary messengers or regulatory proteins. Homology model was visualized with VMD program [32].
###end p 25
###begin p 26
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
###xml 293 295 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 434 436 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
Haplotype analysis of the NTRK1 gene revealed 12 tag SNPs forming no haplotype blocks (Electronic supplementary material - additional file 3). 2 of 12 tag SNPs were exonic: c.1674G>A and c.1810C>T - and they were in moderate linkage disequilibrium (Lewontin coefficient D' = 1.0; LOD = 3.59; r2 = 0.165; 2.6 kb distance). The presence of such disequilibrium was confirmed by our experimental data (D' = 0.568 [0.35-0.7]; LOD = 4.74; r2 = 0.094).
###end p 26
###begin p 27
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 784 790 784 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 1062 1067 1062 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 259 266 <span type="species:ncbi:9606">patient</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
SNPs characterised by MAF>5% were further evaluated to identify possible correlations with clinical and biological prognostic markers of the disease. Results of Cochran-Mantel-Haenszel analysis allowed the merging of data coming from two (Polish and Italian) patient populations. For each SNP heterozygotes and minor allele homozygotes were compared with major allele homozygotes frequencies. Genotype distribution did not deviate significantly from Hardy-Weinberg equilibrium. There were no statistically significant differences in MAF between patients and unaffected controls (Electronic supplementary material - additional file 2). Association study revealed no correlation between particular SNP and the incidence of NB. Spearman rank correlation analyses showed that none of the NTRK1 genotypes was associated with the presence of any of the evaluated NB prognostic markers. Logistic regression analyses identified c.1810C>T polymorphism as an independent statistically significant risk factor for disease recurrence (OR = 13.3; 95%CI: 1.9-94.0) along with MYCN amplification (OR = 9.79; 95%CI: 2.11-45.52) and clinical stage 4 (OR = 4.54; 95%CI: 1.08-19.1); p = 0.009.
###end p 27
###begin p 28
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 621 626 621 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3C, D</xref>
###xml 550 558 <span type="species:ncbi:9606">children</span>
Overall (OS) and event free (EFS) survival rates were analysed for each of the SNPs separately using log-rank tests and Kaplan Meier plots. The presence of c.1810T allele was associated with shorter survival rates (Figure 3). Five-year OS for c.1810CC was 77.6% (95%CI: 68.6-86.6) v. 26.3% (95%CI: 0-66.8) for c.1810CT and c.1810TT (p = 0.020); while 5-year EFS were 73.8% (95%CI: 64.5-83.1) and 26.3% (95%CI: 0-66.8) (p = 0.047), respectively. Inferior survival rates related to the presence of c.1810T allele were even more evident in the group of children under 18 months of age and without MYCN amplification (Figure 3C, D). Here, 5-year OS was 89.2% (95%CI: 80.4-98.0) v. 33.3% (95%CI: 0-83.2) p = 0.0015; while 5-year EFS were 86.9% (95%CI: 77.8-96.0) and 33.3% (95%CI: 0-83.2) p = 0.0067, respectively.
###end p 28
###begin p 29
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 0 206 0 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan-Meier estimates of 5-year OS (A) and EFS (B) for NB patients and 5-year OS (C) and EFS (D) for NB patients under 18 months of age and without <italic>MYCN </italic>amplification with respect to c.1810C&gt;T polymorphism</bold>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier estimates of 5-year OS (A) and EFS (B) for NB patients and 5-year OS (C) and EFS (D) for NB patients under 18 months of age and without MYCN amplification with respect to c.1810C>T polymorphism. Figures A and B show results for the entire group of NB patients (n = 145): 133 patients with NTRK1 c.1810CC genotype and 12 cases with NTRK1 c.1810CT/c.1810TT genotype. Figures C and D show results for the group of NB patients under 18 months of age and without MYCN amplification (n = 84). This subgroup consists of 78 patients with NTRK1 c.1810CC genotype and 6 cases with NTRK1 c.1810CT/c.1810TT genotype.
###end p 29
###begin p 30
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 663 668 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 864 869 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 923 928 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 1272 1277 1272 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 686 693 <span type="species:ncbi:9606">patient</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
###xml 1108 1116 <span type="species:ncbi:9606">patients</span>
###xml 1165 1173 <span type="species:ncbi:9606">patients</span>
The results of univariate analyses were further confirmed by Cox proportional hazard analysis. Firstly, a model inclusive of NTRK1 genotypes and adjusted for classical risk factors (7 variables - Table 2) was assessed. Three parameters were found to be significantly associated with shorter OS, comprising c.1810T allele having HR = 4.54 (95%CI: 1.07-19.3) at p = 0.041 (overall level of significance of the Cox model p = 0.00016). In the second step, backward elimination of features aimed at identification of minimal set of parameters predictive for OS was performed. This further confirmed c.1810T allele to be a significant marker of inferior OS, along with MYCN amplification and patient's age. Inclusion of the information on stage of the disease did not improve the model (data not shown). This finding is probably due to a strong association of stage and MYCN amplification (43% of patients with stage 4 harboured MYCN amplification in their tumours versus only 22% of patients with earlier stages; p = 0.001 by Fisher's exact test) and a strong association between stage and age <18 months (25% of patients with stage 4 were under 18 months versus 72% of patients with earlier stages; p = 0.006 by Fisher's exact test). We did not observe an association between MYCN amplification and c.1810T allele (p = 1.00 by Fisher's exact test) or between age and c.1810T allele (p = 1.00 by Fisher's exact test).
###end p 30
###begin p 31
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
Significance of the NTRK1 genotypes of MAF>5% and clinical and biological features of the disease on long-time OS rates assessed by multivariate Cox hazard regression model (overall significance of the model at p = 0.00016).
###end p 31
###begin p 32
HR - hazard ratio; CI - confidence intervals
###end p 32
###begin p 33
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Besides, in the group of patients under 18 months of age and without MYCN amplification, c.1810T was found to be the only independent prognostic parameter with HR = 26 (95%CI: 2.01-339); p = 0.008.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALK</italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHOX2B</italic>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 555 561 555 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 728 740 728 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 locus </italic>
###xml 743 748 <span type="species:ncbi:9606">human</span>
The basic alteration in NB is developmental arrest of neuronal differentiation and unrestricted proliferation that most probably result from altered expression of genetic factors. Studies of familial cases of NB allowed for identification of two NB susceptibility genes (ALK, PHOX2B) yet their mutations are present in about 10% of sporadic tumours [24,25]. Inability to identify a single major specific tumour suppressor gene as a triggering agent of NB initiation [2] points toward the role played by genes involved in normal noradrenergic development. NTRK1 gene encoding TrkA neurotrophin receptor for NGF, is referred to as a candidate predisposition gene [5]. In this study, we investigated the genetic variability at the NTRK1 locus in human NBs.
###end p 35
###begin p 36
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
Previously, only one study analysed sequence of NTRK1 gene in NBs [13] and that analysis was limited to the region coding TK domain (exons 13-16). This and two other studies of the NTRK1 sequence: in prostate cancer [15] and medullary thyroid carcinoma [14], utilised SSCP as the sole screening method. However, current standards of molecular diagnostics do not recommend SSCP as a single screening procedure for detection of sequence variants because of its low sensitivity of 50-86%, while DHPLC is considered to be the method of choice because of its sensitivity exceeding 99% [26]. In our study, we used both methods. DHPLC vastly outperformed SSCP, allowing for detection of a notably larger number of sequence variants (11/12 versus 5/12 SNPs identified).
###end p 36
###begin p 37
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">locus </italic>
###xml 762 768 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
Although TrkA expression in NBs was reported significantly variable even at the cellular level within a single case [27], the genetic variability at the NTRK1 gene locus was found to be very limited. Non-synonymous polymorphisms were detected in less than 10% of the analysed cases. Furthermore, tag SNPs identified by HapMap project as well as SNPs present in NCBI dbSNP in vast majority are located in the intronic sections of the gene or do not result in amino acid substitution. Besides, according to the results of bioinformatic analyses, the identified non-synonymous polymorphisms, with the exception of c.1810C>T, have minimal theoretical chance of affecting the protein's structure and/or functions. These findings confirm the conservative character of NTRK1 gene sequence; however, it is possible that significant sequence variants are located elsewhere, for instance in currently unknown 3' flanking regulatory elements.
###end p 37
###begin p 38
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALK </italic>
###xml 403 410 403 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHOX2b </italic>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 656 661 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 1042 1047 1042 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYCN </italic>
###xml 1115 1121 1115 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 697 704 <span type="species:ncbi:9606">patient</span>
Even though c.1810C>T has MAF of 6%, from comprehensive statistical analysis of the associations with NB clinical and biological prognostic factors it appears to be an independent unfavourable risk factor in NB patients. c.1810T allele has been detected in 8.7% of sporadic tumours, which is a similar frequency to the mutations observed for the two known familial NB susceptibility genes (ALK = 12.4%, PHOX2b = 4.3%) [24,25]. Presence of c.1810T allele correlated with inferior 5-year OS and EFS and with more frequent relapse of the disease. From the analyses of the Cox hazard regression models, it appears that c.1810T provides additive information to MYCN amplification status and age of the patient, allowing for finest prediction of the eventual outcome of the disease. Interestingly, the stage of the disease was less informative and could be omitted in the model based on minimal set of predictive parameters. The lack of prognostic significance of stage is most probably due to strong associations with other prognostic variables - MYCN amplification and age. These associations were not observed for the NTRK1 c.1810C>T polymorphism.
###end p 38
###begin p 39
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 775 782 <span type="species:ncbi:9606">patient</span>
The additive value of c.1810T allele to the current clinical prognostic markers should be, however, assessed on a prospective, more coherent, group of patients. In the current study, patients were enrolled in two countries over 20 years, thus they received a range of treatment protocols. Also, histopathological assessment was modified over the time and not all the samples could be assessed in accordance with the revised INPC. Interestingly, IT patients were diagnosed with lower stages of the disease and at a younger age, which is most probably related to better access to medical imaging techniques in Italy and thus higher incidence of incidentalomas diagnosed before overt clinical symptoms of advanced disease became apparent. The above-presented discrepancy in the patient population and the fact that the study was retrospective might, however, result in some limitation of the force of the study.
###end p 39
###begin p 40
The mechanisms through which c.1810T variant could trigger and/or modify oncogenic events in embryonal NCC are only hypothetical at this time; however, our preliminary data provide an interesting starting point for further studies, possibly using a genome-wide association methodology.
###end p 40
###begin p 41
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1111 1120 1109 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 1137 1142 1135 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1145 1147 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 678 685 <span type="species:ncbi:9606">patient</span>
Several points strongly support the significance of our finding; a) first, the evidence of the observed correlations was highly significant, both in univariate and multivariate analyses. Similarly, in the previous study of 63 NBs [13], there was a trend for the c.1810T to be present in cases having advanced stages of the disease; b) there were no major differences in allelic frequencies among two European populations that would explain these findings on the basis of population stratification. Linkage disequilibrium between c.1674G>A and c.1810C>T was present in both groups of patients, and also in four populations from HapMap database, thus the results obtained in both patient groups most probably refer to the same genetic effect; c) the bioinformatic analysis of the c.1810C>T showed that substitution of the corresponding amino acid (His-->Tyr) affects a conservative residue of the TK domain. This substitution changes the chemical properties of a residue in conserved position, which may possibly alter the function of TK domain. From analysis of our homology model as well as from the results of in vitro studies by Mardy et al. [28], it appears that c.1810C>T does not inhibit the ability for autophosphorylation of TK domain. It may, however, be involved in interactions with the residues of the kinase insert loop. The exact role of this fragment of TK, specific for TrkA, remains unknown though it may be involved in signal transduction through interfering with the adaptor molecules.
###end p 41
###begin p 42
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 247 255 <span type="species:ncbi:9606">children</span>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 634 639 <span type="species:ncbi:9606">child</span>
Finally, a few methodological considerations regarding peculiarities of gene association studies performed on a paediatric oncologic experimental group should be pointed out. The relatively low incidence of neuroblastoma of 10.9 cases per million children yearly [29] affects the available size of patient sample group. In order to overcome this limitation, patients representing two European populations were enrolled in the study after initial validation of their correspondence using the Cochran-Mantel-Haenszel analysis. Another important methodological issue is related to the design of an adequate control group. If age-matched child controls had been used in the study, a screening for clinically inert tumour would have been required, however this might have created an ethical dilemma. Therefore, similarly to other studies in the field [30], healthy adult volunteers were chosen as controls, even if such a decision was related to some decrease in the force of the study. Moreover, even though the study was aimed at detection of constitutional mutations, since the available material collected by both national tissue banks consisted of primary NB tumours, tumour DNA was analysed. A similar approach is applied in studies of other researchers [24,25] because tumour biology is the area of primary interest from the clinical point of view. Besides, tumour samples are the routine material available for molecular assessment in research setting. Nevertheless, supplementary nested study of the corresponding germline DNA, derived from peripheral blood leukocytes of the cases where such material was available, was performed to provide confirmation of the constitutional character of the analysed SNPs.
###end p 42
###begin title 43
Conclusions
###end title 43
###begin p 44
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALK </italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHOX2b</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
We propose NTRK1 c.1810C>T polymorphism as a new prognostic factor in NB. In contrast to known NB susceptibility genes (ALK and PHOX2b), NTRK1 c.1810C>T polymorphism does not predispose to NB development. Conversely, its presence confers worse prognosis to the affected patients. Nevertheless, further studies are needed to disclose its effect on TrkA receptor structure and/or function, for instance by comparing the expression levels of wild type and mutated TrkA at RNA and protein levels.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
###xml 80 86 <span type="species:ncbi:9606">people</span>
None of the authors declare any financial and personal relationships with other people or organizations that could inappropriately influence (bias) the work. This includes employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
###xml 409 419 409 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-silico </italic>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
BL conceived of the study, carried out the molecular genetic studies, performed the statistical analysis, participated in the sequence alignment and drafted the manuscript. ED participated in the design of the study and its coordination and provided clinical data. PS carried out the molecular genetic studies. GP coordinated the study of the Italian patients and helped to draft the manuscript. SZ performed in-silico analyses and helped to draft the manuscript. EIS, DP, AC provided tumor samples and clinical data and coordinated the study of the Polish patients. WB participated in statistical analysis and helped to draft the manuscript. JL conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 48
###begin title 49
Pre-publication history
###end title 49
###begin p 50
The pre-publication history for this paper can be accessed here:
###end p 50
###begin p 51

###end p 51
###begin title 52
Supplementary Material
###end title 52
###begin title 53
Additional file 1
###end title 53
###begin p 54
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The identified new sequence variants of the <italic>NTRK1 </italic>gene</bold>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
The identified new sequence variants of the NTRK1 gene. Detailed list of all (exonic and intronic) new sequence variants of the NTRK1 gene identified in the study.
###end p 54
###begin p 55
Click here for file
###end p 55
###begin title 56
Additional file 2
###end title 56
###begin p 57
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 0 129 0 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The frequencies of the common (MAF&gt;5%) sequence variants of the <italic>NTRK1 </italic>gene in the two groups of patients and the healthy controls</bold>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
The frequencies of the common (MAF>5%) sequence variants of the NTRK1 gene in the two groups of patients and the healthy controls. Details regarding frequencies of the SNPs with MAF>5% in the analyzed populations and the control group along with the results of the Hardy-Weinberg equilibrium analysis.
###end p 57
###begin p 58
Click here for file
###end p 58
###begin title 59
Additional file 3
###end title 59
###begin p 60
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 0 122 0 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Haplotype analysis of the SNPs representative for <italic>NTRK1 </italic>locus based on the data retrieved from the HapMap Project database</bold>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK1 </italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 654 665 654 665 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WHITE COLOR</bold>
###xml 698 708 698 708 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BLUE COLOR</bold>
###xml 753 781 753 781 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INTENSIVITY OF THE RED COLOR</bold>
Haplotype analysis of the SNPs representative for NTRK1 locus based on the data retrieved from the HapMap Project database. Results of the haplotype analysis of the SNPs representative for NTRK1 locus based on the data retrieved from the HapMap Project database. The analysis was performed using Haploview software [22]. In the upper part of the scheme physical map of the corresponding fragment of the chromosome is given, the middle part of the scheme shows exact intronic/exonic localization of the SNPs and the lower part illustrates identified associations. (rs6334 - c.1674G>A; rs6336 - c.1810C>T). Color code reflects the strength of association: WHITE COLOR: D' < 1, LOD<2 - insignificant; BLUE COLOR: D' = 1 LOD<2 high degree of recombination; INTENSIVITY OF THE RED COLOR: D' < 1; LOD = 2 reflects the strength of association, the maximum of intensity is reached at D' = 1, LOD = 2 - high level of association. The numbers on the diamonds show D' value multiplied by 100.
###end p 60
###begin p 61
Click here for file
###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
###xml 447 455 <span type="species:ncbi:9606">Children</span>
The study was supported by the Polish Ministry of Science (Grant N. 2 P05A 005 29) and the Italian Neuroblastoma Foundation. BS Lipska was supported by doctoral fellowship from the Postgraduate School of Molecular Medicine, Warsaw Poland and partially by the Italian Government Fellowship for Young Researchers. We are grateful to dr. Alberto Garaventa for providing clinical data and dr. Claudio Gambini for tumor specimens, both from G. Gaslini Children's' Hospital, Genova, Italy; to dr. Iwona Cymerman from International Institute of Molecular and Cell Biology, Warsaw, Poland for help in bioinformatics analysis and to dr. Rafal Dziadziuszko from Medical University of Gdansk, Poland and dr. Andrzej Sokolowski from Cracow University of Economics, Cracow, Poland for help in statistical analyses.
###end p 63
###begin article-title 64
Fetal and neonatal neuroblastoma. Retrospective review of 271 cases
###end article-title 64
###begin article-title 65
Neuroblastoma
###end article-title 65
###begin article-title 66
Prognostic discrimination among neuroblastomas according to Ha-ras/TrkA gene expression
###end article-title 66
###begin article-title 67
Neurotrophin signaling: many exciting surprises!
###end article-title 67
###begin article-title 68
Neural crest development and neuroblastoma: the genetic and biological link
###end article-title 68
###begin article-title 69
Trk receptor kinases: a bridge between cancer and neural development
###end article-title 69
###begin article-title 70
Effects of Schwann cell secreted factors on PC12 cell neuritogenesis and survival
###end article-title 70
###begin article-title 71
###xml 88 93 <span type="species:ncbi:9606">human</span>
Molecular dissection of Trk-A signal transduction pathways mediating differentiation in human neuroblastoma
###end article-title 71
###begin article-title 72
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH) and computer-assisted microscopy
###end article-title 72
###begin article-title 73
Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes
###end article-title 73
###begin article-title 74
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
###end article-title 74
###begin article-title 75
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
###end article-title 75
###begin article-title 76
###xml 107 112 <span type="species:ncbi:9606">human</span>
Detection of DNA polymorphisms and point mutations of high-affinity nerve growth factor receptor (TrkA) in human neuroblastoma
###end article-title 76
###begin article-title 77
###xml 73 78 <span type="species:ncbi:9606">human</span>
Mutational analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma
###end article-title 77
###begin article-title 78
Mutational analysis of the TrkA gene in prostate cancer
###end article-title 78
###begin article-title 79
Genetics of congenital insensivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor
###end article-title 79
###begin article-title 80
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma
###end article-title 80
###begin article-title 81
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland
###end article-title 81
###begin article-title 82
Pfam Database of Protein Families
###end article-title 82
###begin article-title 83
Protein Data Bank
###end article-title 83
###begin article-title 84
International HapMap Project
###end article-title 84
###begin article-title 85
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 85
###begin article-title 86
Crystal structure if the MuSK tyrosine kinase: insights into receptor autoregulation
###end article-title 86
###begin article-title 87
Identification of ALK as a major familial neuroblastoma predisposition gene
###end article-title 87
###begin article-title 88
Rare occurrence of PHOX2b mutations in sporadic neuroblastomas
###end article-title 88
###begin article-title 89
Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review
###end article-title 89
###begin article-title 90
###xml 71 76 <span type="species:ncbi:9606">human</span>
Association of neurotrophin receptor expression and differentiation in human neuroblastoma
###end article-title 90
###begin article-title 91
Congenital insensitivity to pain with anhydrisis (CIPA): effect of TRKA (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor
###end article-title 91
###begin article-title 92
###xml 49 57 <span type="species:ncbi:9606">children</span>
Neuroblastoma incidence and survival in European children (1978-1997). Report from Automated Childchood Cancer Information System project
###end article-title 92
###begin article-title 93
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients
###end article-title 93
###begin article-title 94
Tyr-701 is a new regulatory site for neurotrophin receptor TrkA trafficking and function
###end article-title 94
###begin article-title 95
VMD - Visual Molecular Dynamics
###end article-title 95

